Yves Vanrenterghem is a scholar working on Transplantation, Surgery and Nephrology.
According to data from OpenAlex, Yves Vanrenterghem has authored 267 papers receiving a total of 12.7k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Transplantation, 76 papers in Surgery and 71 papers in Nephrology. Recurrent topics in Yves Vanrenterghem's work include Renal Transplantation Outcomes and Treatments (139 papers), Organ Transplantation Techniques and Outcomes (50 papers) and Pharmacological Effects and Toxicity Studies (46 papers). Yves Vanrenterghem is often cited by papers focused on Renal Transplantation Outcomes and Treatments (139 papers), Organ Transplantation Techniques and Outcomes (50 papers) and Pharmacological Effects and Toxicity Studies (46 papers). Yves Vanrenterghem collaborates with scholars based in Belgium, United States and Spain. Yves Vanrenterghem's co-authors include Dirk Kuypers, Pieter Evenepoel, Kristin Verbeke, Bert Bammens, Bart Maes, Maarten Naesens, Björn Meijers, Hylke de Jonge, Kathleen Claes and Evelyne Lerut and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.
In The Last Decade
Yves Vanrenterghem
260 papers
receiving
12.4k citations
Hit Papers
What are hit papers?
Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
2010690 citationsFlavio Vincenti, B Charpentier et al.American Journal of Transplantationprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Yves Vanrenterghem
Since
Specialization
Citations
This map shows the geographic impact of Yves Vanrenterghem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves Vanrenterghem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves Vanrenterghem more than expected).
Fields of papers citing papers by Yves Vanrenterghem
This network shows the impact of papers produced by Yves Vanrenterghem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves Vanrenterghem. The network helps show where Yves Vanrenterghem may publish in the future.
Co-authorship network of co-authors of Yves Vanrenterghem
This figure shows the co-authorship network connecting the top 25 collaborators of Yves Vanrenterghem.
A scholar is included among the top collaborators of Yves Vanrenterghem based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Yves Vanrenterghem. Yves Vanrenterghem is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Jonge, Hylke de, Maarten Naesens, Yves Vanrenterghem, & Dirk Kuypers. (2009). The Pregnane X Receptor (NR1I2) C-25385T Single Nucleotide Polymorphism (SNP) Does Not Affect Tacrolimus Pharmacokinetics in a Large Cohort of Renal Transplant Recipients. American Journal of Transplantation. 9. 571–572.1 indexed citations
6.
Larsen, Christian P., B Charpentier, J.M. Grinyó, et al.. (2009). 3-Year Safety Profile of Belatacept in Kidney Transplant Recipients from the BENEFIT and BENEFIT-EXT Studies. Transplant International. 22. 90–90.4 indexed citations
Meier-Kriesche, H.-U., Jesse D. Schold, Yves Vanrenterghem, Philip F. Halloran, & Henrik Ekberg. (2007). Factors associated with BMI increases early after renal transplantation: Evidence from the symphony study. American Journal of Transplantation. 7. 464–464.1 indexed citations
12.
Vanrenterghem, Yves, et al.. (2007). Levels and progression of parameters associated with metabolic syndrome by immunosuppressive regimen: Evidence from the symphony study. American Journal of Transplantation. 7. 186–186.3 indexed citations
13.
Ekberg, Henrik, Jesse D. Schold, Yves Vanrenterghem, Herwig‐Ulf Meier‐Kriesche, & Philip F. Halloran. (2007). Progression of renal function by donor quality and the modifying effect of immunosuppression: Evidence from the Symphony study. Transplant International. 20. 26–26.1 indexed citations
14.
Vincenti, Flavio, Yves Vanrenterghem, Björn Nashan, et al.. (2005). The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose/withdrawal and standard dose) to optimize renal function in renal allograft recipients - 18 month results. American Journal of Transplantation. 5. 539–540.6 indexed citations
Donck, J, Jozef Vermylen, Yves Vanrenterghem, Désiré Collen, & Paul Holvoet. (1995). Direct quantitation of oxidized low-density-lipoprotein (oxldl) and assessment of its pole in atherothrombosis in end-stage renal-disease (esrd) patients. Journal of the American Society of Nephrology. 6(3). 576–576.8 indexed citations
Vanrenterghem, Yves, L Roels, Antoon Lerut, et al.. (1985). Evaluation of cyclosporine in a center with high survival rates using conventional immunosuppression. Transplantation Proceedings. 17(6). 2666–2668.2 indexed citations
20.
Vanrenterghem, Yves, et al.. (1978). Fractional clearances of dextran and dextran sulfate in a new model of proteinuria in dog. European Journal of Clinical Investigation. 8(5). 332–333.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.